Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

NCT02952534 is registered in ClinicalTrials.gov with pharmaand GmbH as lead sponsor.

NCT NCT02952534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02952534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Lead sponsor
pharmaand GmbH
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2017
Completion date
July 27, 2021
Enrollment
277 (actual)
Sites
149

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer